

Dear Author,

Here are the final proofs of your article. Please check the proofs carefully.

Please note that at this stage you should only be checking for errors introduced during the production process. Please pay particular attention to the following when checking the proof:

- Author names. Check that each author name is spelled correctly, and that names appear in the correct order of first name followed by family name. This will ensure that the names will be indexed correctly (for example if the author's name is 'Patel, J. ', she will be cited as ' Jane Patel ').
- Affiliations. Check that all authors are cited with the correct affiliations, that the author who will receive correspondence has been identified with an asterisk (*), and that all equal contributors have been identified with a well sign (#).
- Ensure that the main text is complete.
- Check that figures, tables and their legends are included and in the correct order.
- Look to see that queries that were raised during copy-editing or typesetting have been resolved.
- Confirm that all web links are correct and working.
- Ensure that special characters and equations are displaying correctly.
- Check that additional or supplementary files can be opened and are correct.

Changes in scientific content cannot be made at this stage unless the request has already been approved. This includes changes to title or authorship, new results, or corrected values.

How to return your corrections

Returning your corrections via email:

- Annotate the proof PDF with your corrections.
- Remember to include the journal title, manuscript number, and your name when sending your response via email.

After you have submitted your corrections, you will receive email notification from our production team that your article has been published in the final version. All changes at this stage are final. We will not be able to make any further changes after publication.

Kind regards,

In vitro geroscience. Screening anti-aging drug combinations for neurodegenerative diseases

Soroosh Fatemi^a, Joo Young Park^a, Warren Ladiges^{a,*}

^a Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA, USA.

Abstract

Geroscience is based on the concept that therapeutic approaches that work for aging will also work for age-related diseases, including neurodegenerative diseases such as Alzheimer's disease (AD). Single drugs have been ineffective in treating AD, so it seems reasonable to consider using multiple drugs in combination (cocktails) for a more effective treatment approach. However, initial screening of drug cocktails in animal models is costly and time-consuming. The human neuroblastoma cell line SH-SY5Y has neuronal properties and can be stressed with chemicals or transfected with adeno-associated virus (AAV) A β and/or pTau vectors for an *in vitro* model of neurotoxicity. Drug cocktails can then be easily screened for intervention efficacy compared to each individual drug in the cocktail.

Keywords: Drug cocktails, anti-aging drugs, geroscience, neuroblastoma cell line, Alzheimer's disease

Alzheimer's disease (AD) is a common neurodegenerative disease for which no single drug therapy has been successful. The concept of geroscience is that therapeutic approaches that work for aging will also work for age-related diseases, including AD. Therefore, rather than focusing on testing a single drug, it seems reasonable to consider using multiple drugs in combination (a cocktail) for a more effective treatment strategy. However, testing drug cocktails in animal models is expensive and time-consuming.

A simple and inexpensive system is needed. In this regard, Mairuae *et al.* recently published an article describing the use of a human neuroblastoma cell line to test the ability of a combination of mulberry fruit and leaf extracts to prevent hydrogen peroxide-induced cytotoxicity [1]. They showed that the protective effect was most pronounced with the extract combination compared to each individual extract, suggesting an interaction between the two extracts and that the extract combination hit a broader pathway of cellular targets.

Their observation reinforces the critical importance of using drug combinations to treat AD. However, this type of

approach has not received the attention it deserves, mainly because there is still a mystery as to what causes AD, and in fact there are most likely are multiple causes. The mainstream thinking is that using drug combinations to treat AD is a shotgun approach and not scientifically sound. This is counterintuitive to the geroscience concept, which is based on the underlying principle that if a drug cocktail is effective in delaying aging, then it will be effective in delaying the dementia and neuropathology associated with AD. Our laboratory has recently shown that a combination of rapamycin, acarbose, and phenylbutyrate is effective in enhancing resilience to aging in C57BL/6 and HET3 mice [2]. We also showed that the drug combination delayed the onset of age-related cognitive impairment [3], suggesting that it would be a promising combination to test for delaying or preventing AD.

Part of the reluctance to embrace drug combinations for the treatment of AD may be the high cost and intensive effort required to conduct such studies in animal models. An *in vitro* cell culture system would be ideal for screening drug combinations in a cost-effective and timely manner, as described by Mairuae *et al.* [1]. They used the SH-SY5Y human neuroblastoma cell line, which is of neuronal origin and exhibits neuronal cell properties including cytotoxicity influence. To use this cell line to screen drug combinations for AD, we performed transfections with adeno-associated virus (AAV) vectors containing sequences for A β 42 and pTau. Drugs that are soluble in aqueous solutions, such as peptides, are easily tested in this model system. However, many insoluble drugs can be solubilized in solvents such as DMSO and still be tested

* Corresponding author: Warren Ladiges

Mailing address: Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA, USA.

Email: wladiges@uw.edu

Received: 14 June 2023 / Accepted: 14 June 2023

Published: XX June 2023

under the right conditions. Since we are not looking for a specific target, there is no need to use a reporter system. Instead, we have developed a streamlined immunohistochemistry format with multiple neuropathological markers as readouts to measure the efficacy of the drug cocktail compared to each individual drug.

In conclusion, the use of the SH-SY5Y neuroblastoma cell line is an example of a viable, robust and inexpensive *in vitro* system for screening anti-aging drug cocktails as effective therapeutics for neuronal cell damage associated with neurodegenerative conditions such as AD. By testing different combinations of drugs targeting a wider range of aging pathways, it will be possible to screen candidate drug cocktails quickly and efficiently, justifying the time and expense of larger-scale animal studies.

Declarations

Availability of data and materials: Not applicable.

Financial support and sponsorship: None.

Conflicts of interest: Warren Ladiges is a member of the editorial board of *Aging Pathobiology and Therapeutics*. The authors declare that they have no conflicts and were not involved in the journal's review or decision regarding this manuscript.

References

1. Mairuae N, Palachai N, & Noisa P. The neuroprotective effects of the combined extract of mulberry fruit and mulberry leaf against hydrogen peroxide-induced cytotoxicity in SH-SY5Y Cells. *BMC Complement Med Ther*, 2023, 23(1): 117-133. [[Crossref](#)]
2. Jiang Z, Wang J, Imai D, Snider T, Klug J, Mangalindan R, *et al*. Short term treatment with a cocktail of rapamycin, acarbose and phenylbutyrate delays aging phenotypes in mice. *Sci Rep*, 2022, 12(1): 7300-7312. [[Crossref](#)]
3. Zhou J, Qianpei H, & Warren L. A cocktail of rapamycin, acarbose and phenylbutyrate prevents age-related cognitive decline in mice by altering aging pathways. *bioRxiv*, 2022: 2022.2009.2007.506968. [[Crossref](#)]

Cite this article as: Fatemi S, Park JY, & Ladiges W. *In vitro* geroscience. Screening anti-aging drug combinations for neurodegenerative diseases. *Aging Pathobiol Ther*, 2023, 5(2): xx-xx. doi: 10.31491/APT.2023.06.xxx

Author Query Form

Dear Author,

During the copy-editing of your paper, the following queries arose.

Please refer to the query reference call out numbers in the page proofs and respond to each by marking the necessary comments using the PDF annotation tools.

Please remember illegible or unclear comments and corrections may delay publication.

Many thanks for your assistance.

QueryReference	Query	Remark
Q1	Please check that all author information is correct?	
Q2	Please confirm that the corresponding author's address is correct?	
Q3	Please confirm whether there are any content and spelling errors in the full text?	
Q4	Please check if the References are correct?	